A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
← catalyst calendarNCT06869551 · readout in 1,295 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
47
Countries
Brazil, Bulgaria, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-13 | actual | When the study began enrolling |
| Primary completion | 2030-03-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-03-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Juvenile Psoriatic Arthritis
Interventions
- Drug: Deucravacitinib
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to first flare during the withdrawal period
measured From week 16 up to week 42
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed